Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.

Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP.

Science. 2013 Nov 29;342(6162):1094-8. doi: 10.1126/science.1241908.

2.

Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.

Kimbung S, Chang CY, Bendahl PO, Dubois L, Thompson JW, McDonnell DP, Borgquist S.

Endocr Relat Cancer. 2017 Jul;24(7):339-349. doi: 10.1530/ERC-16-0533. Epub 2017 Apr 25.

3.

27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.

Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA, Umetani M, Euhus DM, Xie Y, Shaul PW.

Cell Rep. 2013 Nov 14;5(3):637-45. doi: 10.1016/j.celrep.2013.10.006. Epub 2013 Nov 7.

4.

On estrogen, cholesterol metabolism, and breast cancer.

Warner M, Gustafsson JA.

N Engl J Med. 2014 Feb 6;370(6):572-3. doi: 10.1056/NEJMcibr1315176. No abstract available.

PMID:
24499217
5.

Obesity, cholesterol metabolism, and breast cancer pathogenesis.

McDonnell DP, Park S, Goulet MT, Jasper J, Wardell SE, Chang CY, Norris JD, Guyton JR, Nelson ER.

Cancer Res. 2014 Sep 15;74(18):4976-82. doi: 10.1158/0008-5472.CAN-14-1756. Epub 2014 Jul 24.

6.

Cholesterol and breast cancer pathophysiology.

Nelson ER, Chang CY, McDonnell DP.

Trends Endocrinol Metab. 2014 Dec;25(12):649-55. doi: 10.1016/j.tem.2014.10.001. Epub 2014 Nov 4. Review.

7.

Breast cancer and (25R)-26-hydroxycholesterol.

Javitt NB.

Steroids. 2015 Dec;104:61-4. doi: 10.1016/j.steroids.2015.08.012. Epub 2015 Aug 20. Review.

PMID:
26299212
8.

De novo synthesis of steroids and oxysterols in adipocytes.

Li J, Daly E, Campioli E, Wabitsch M, Papadopoulos V.

J Biol Chem. 2014 Jan 10;289(2):747-64. doi: 10.1074/jbc.M113.534172. Epub 2013 Nov 26.

9.

Hematopoietic overexpression of Cyp27a1 reduces hepatic inflammation independently of 27-hydroxycholesterol levels in Ldlr(-/-) mice.

Hendrikx T, Jeurissen ML, Bieghs V, Walenbergh SM, van Gorp PJ, Verheyen F, Houben T, Guichot YD, Gijbels MJ, Leitersdorf E, Hofker MH, Lütjohann D, Shiri-Sverdlov R.

J Hepatol. 2015 Feb;62(2):430-6. doi: 10.1016/j.jhep.2014.09.027. Epub 2014 Oct 2.

PMID:
25281859
10.

The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis.

DuSell CD, Nelson ER, Wang X, Abdo J, Mödder UI, Umetani M, Gesty-Palmer D, Javitt NB, Khosla S, McDonnell DP.

Endocrinology. 2010 Aug;151(8):3675-85. doi: 10.1210/en.2010-0080. Epub 2010 May 25.

11.

The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells.

Baek AE, Yu YA, He S, Wardell SE, Chang CY, Kwon S, Pillai RV, McDowell HB, Thompson JW, Dubois LG, Sullivan PM, Kemper JK, Gunn MD, McDonnell DP, Nelson ER.

Nat Commun. 2017 Oct 11;8(1):864. doi: 10.1038/s41467-017-00910-z.

12.

The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha.

Umetani M, Ghosh P, Ishikawa T, Umetani J, Ahmed M, Mineo C, Shaul PW.

Cell Metab. 2014 Jul 1;20(1):172-82. doi: 10.1016/j.cmet.2014.05.013. Epub 2014 Jun 19.

13.

The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer.

McDonnell DP, Chang CY, Nelson ER.

Climacteric. 2014 Dec;17 Suppl 2:60-5. doi: 10.3109/13697137.2014.966949. Epub 2014 Oct 16.

14.

On the regulatory role of side-chain hydroxylated oxysterols in the brain. Lessons from CYP27A1 transgenic and Cyp27a1(-/-) mice.

Ali Z, Heverin M, Olin M, Acimovic J, Lövgren-Sandblom A, Shafaati M, Båvner A, Meiner V, Leitersdorf E, Björkhem I.

J Lipid Res. 2013 Apr;54(4):1033-43. doi: 10.1194/jlr.M034124. Epub 2013 Jan 2.

15.

CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer.

Alfaqih MA, Nelson ER, Liu W, Safi R, Jasper JS, Macias E, Geradts J, Thompson JW, Dubois LG, Freeman MR, Chang CY, Chi JT, McDonnell DP, Freedland SJ.

Cancer Res. 2017 Apr 1;77(7):1662-1673. doi: 10.1158/0008-5472.CAN-16-2738. Epub 2017 Jan 27.

16.

Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.

Mast N, Lin JB, Pikuleva IA.

Mol Pharmacol. 2015 Sep;88(3):428-36. doi: 10.1124/mol.115.099598. Epub 2015 Jun 16.

17.

Evidence of pomegranate methanolic extract in antagonizing the endogenous SERM, 27-hydroxycholesterol.

Vini R, Juberiya AM, Sreeja S.

IUBMB Life. 2016 Feb;68(2):116-21. doi: 10.1002/iub.1465. Epub 2016 Jan 12.

18.

The ROS-mediated activation of STAT-3/VEGF signaling is involved in the 27-hydroxycholesterol-induced angiogenesis in human breast cancer cells.

Zhu D, Shen Z, Liu J, Chen J, Liu Y, Hu C, Li Z, Li Y.

Toxicol Lett. 2016 Dec 15;264:79-86. doi: 10.1016/j.toxlet.2016.11.006. Epub 2016 Nov 14.

PMID:
27856279
19.

27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.

He S, Nelson ER.

Maturitas. 2017 Oct;104:29-35. doi: 10.1016/j.maturitas.2017.07.014. Epub 2017 Jul 31. Review.

PMID:
28923174
20.

Re-adopting classical nuclear receptors by cholesterol metabolites.

Umetani M.

J Steroid Biochem Mol Biol. 2016 Mar;157:20-6. doi: 10.1016/j.jsbmb.2015.11.002. Epub 2015 Nov 10. Review.

Supplemental Content

Support Center